B cell depletion enhances T regulatory cell activity essential in the suppression of arthritis

Journal of Immunology

Volumn 187, Issue 9, 2011, Pages 4900-4906

  Hamel, Keith M ^a   Cao, Yanxia ^a   Ashaye, Susan ^a   Wang, Yumei ^a   Dunn, Robert ^b   Kehry, Marilyn R ^b   Glant, Tibor T ^a   Finnegan, Alison ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD20 ANTIBODY; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIGENICITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CELL EXPANSION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; FEMALE; LYMPHOCYTE DEPLETION; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; RHEUMATOID ARTHRITIS; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTE SUBSETS; EPITOPES, T-LYMPHOCYTE; FEMALE; INFLAMMATION; LYMPHOCYTE DEPLETION; LYMPHOPENIA; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; PROTEOGLYCANS; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, REGULATORY;

EID: 80555149788     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1101844     Document Type: Article

References (58)

1. Firestein, G. S. 2003. Evolving concepts of rheumatoid arthritis. Nature 423: 356-361. (Pubitemid 40852711)
2. Edwards, J. C., L. Szczepanski, J. Szechinski, A. Filipowicz-Sosnowska, P. Emery, D. R. Close, R. M. Stevens, and T. Shaw. 2004. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N. Engl. J. Med. 350: 2572-2581. (Pubitemid 38758544)
3. Emery, P., R. Fleischmann, A. Filipowicz-Sosnowska, J. Schechtman, L. Szczepanski, A. Kavanaugh, A. J. Racewicz, R. F. van Vollenhoven, N. F. Li, S. Agarwal, et al. DANCER Study Group. 2006. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum. 54: 1390-1400.
4. Cohen, S. B., P. Emery, M. W. Greenwald, M. Dougados, R. A. Furie, M. C. Genovese, E. C. Keystone, J. E. Loveless, G. R. Burmester, M. W. Cravets, et al. REFLEX Trial Group. 2006. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 54: 2793-2806. (Pubitemid 44497758)
5. Cambridge, G., W. Stohl, M. J. Leandro, T. S. Migone, D. M. Hilbert, and J. C. Edwards. 2006. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54: 723-732.
6. Lund, F. E., and T. D. Randall. 2010. Effector and regulatory B cells: modulators of CD4(+) T cell immunity. Nat. Rev. Immunol. 10: 236-247.
7. Sfikakis, P. P., J. N. Boletis, and G. C. Tsokos. 2005. Rituximab anti-B-cell therapy in systemic lupus erythematosus: pointing to the future. Curr. Opin. Rheumatol. 17: 550-557. (Pubitemid 41527814)
8. Eming, R., A. Nagel, S. Wolff-Franke, E. Podstawa, D. Debus, and M. Hertl. 2008. Rituximab exerts a dual effect in pemphigus vulgaris. J. Invest. Dermatol. 128: 2850-2858.
9. Stasi, R., G. Del Poeta, E. Stipa, M. L. Evangelista, M. M. Trawinska, N. Cooper, and S. Amadori. 2007. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood 110: 2924-2930. (Pubitemid 350006946)
10. Yanaba, K., Y. Hamaguchi, G. M. Venturi, D. A. Steeber, E. W. St Clair, and T. F. Tedder. 2007. B cell depletion delays collagen-induced arthritis in mice: arthritis induction requires synergy between humoral and cell-mediated immunity. J. Immunol. 179: 1369-1380.
11. Saadoun, D., M. Rosenzwajg, D. Landau, J. C. Piette, D. Klatzmann, and P. Cacoub. 2008. Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis. Blood 111: 5334-5341.
12. Hamel, K., P. Doodes, Y. Cao, Y. Wang, J. Martinson, R. Dunn, M. R. Kehry, B. Farkas, and A. Finnegan. 2008. Suppression of proteoglycan-induced arthritis by anti-CD20 B Cell depletion therapy is mediated by reduction in autoantibodies and CD4+ T cell reactivity. J. Immunol. 180: 4994-5003.
13. Glant, T. T., K. Mikecz, A. Arzoumanian, and A. R. Poole. 1987. Proteoglycaninduced arthritis in BALB/c mice. Clinical features and histopathology. Arthritis Rheum. 30: 201-212. (Pubitemid 17060776)
14. Glant, T. T., G. Cs-Szabó, H. Nagase, J. J. Jacobs, and K. Mikecz. 1998. Progressive polyarthritis induced in BALB/c mice by aggrecan from normal and osteoarthritic human cartilage. Arthritis Rheum. 41: 1007-1018. (Pubitemid 28265403)
15. Glant, T. T., A. Finnegan, and K. Mikecz. 2003. Proteoglycan-induced arthritis: immune regulation, cellular mechanisms, and genetics. Crit. Rev. Immunol. 23: 199-250. (Pubitemid 37204432)
16. Finnegan, A., K. Mikecz, P. Tao, and T. T. Glant. 1999. Proteoglycan (aggrecan)-induced arthritis in BALB/c mice is a Th1-type disease regulated by Th2 cytokines. J. Immunol. 163: 5383-5390.
17. Tunyogi-Csapo, M., K. Kis-Toth, M. Radacs, B. Farkas, J. J. Jacobs, A. Finnegan, K. Mikecz, and T. T. Glant. 2008. Cytokine-controlled RANKL and osteoprotegerin expression by human and mouse synovial fibroblasts: fibroblast-mediated pathologic bone resorption. Arthritis Rheum. 58: 2397-2408.
18. Doodes, P. D., Y. Cao, K. M. Hamel, Y. Wang, R. L. Rodeghero, K. Mikecz, T. T. Glant, Y. Iwakura, and A. Finnegan. 2010. IFN-gamma regulates the requirement for IL-17 in proteoglycan-induced arthritis. J. Immunol. 184: 1552-1559.
19. O'Neill, S. K., M. J. Shlomchik, T. T. Glant, Y. Cao, P. D. Doodes, and A. Finnegan. 2005. Antigen-specific B cells are required as APCs and autoantibody-producing cells for induction of severe autoimmune arthritis. J. Immunol. 174: 3781-3788. (Pubitemid 40354091)
20. O'Neill, S. K., Y. Cao, K. M. Hamel, P. D. Doodes, G. Hutas, and A. Finnegan. 2007. Expression of CD80/86 on B cells is essential for autoreactive T cell activation and the development of arthritis. J. Immunol. 179: 5109-5116.
21. Sakaguchi, S., T. Yamaguchi, T. Nomura, and M. Ono. 2008. Regulatory T cells and immune tolerance. Cell 133: 775-787. (Pubitemid 351707693)
22. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M. Toda. 1995. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155: 1151-1164.
23. Fontenot, J. D., M. A. Gavin, and A. Y. Rudensky. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4: 330-336. (Pubitemid 36432314)
24. Fontenot, J. D., J. P. Rasmussen, L. M. Williams, J. L. Dooley, A. G. Farr, and A. Y. Rudensky. 2005. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity 22: 329-341. (Pubitemid 40387475)
25. Shevach, E. M. 2009. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 30: 636-645.
26. Viglietta, V., C. Baecher-Allan, H. L. Weiner, and D. A. Hafler. 2004. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J. Exp. Med. 199: 971-979. (Pubitemid 38481088)
27. Ehrenstein, M. R., J. G. Evans, A. Singh, S. Moore, G. Warnes, D. A. Isenberg, and C. Mauri. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 200: 277-285. (Pubitemid 39031247)
28. Lawson, C. A., A. K. Brown, V. Bejarano, S. H. Douglas, C. H. Burgoyne, A. S. Greenstein, A. W. Boylston, P. Emery, F. Ponchel, and J. D. Isaacs. 2006. Early rheumatoid arthritis is associated with a deficit in the CD4+CD25high regulatory T cell population in peripheral blood. Rheumatology (Oxford) 45: 1210-1217. (Pubitemid 44548851)
29. Lindley, S., C. M. Dayan, A. Bishop, B. O. Roep, M. Peakman, and T. I. Tree. 2005. Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes. Diabetes 54: 92-99. (Pubitemid 40105099)
30. Sugiyama, H., R. Gyulai, E. Toichi, E. Garaczi, S. Shimada, S. R. Stevens, T. S. McCormick, and K. D. Cooper. 2005. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. 174: 164-173. (Pubitemid 40007402)
31. Wei, J., O. Duramad, O. A. Perng, S. L. Reiner, Y. J. Liu, and F. X. Qin. 2007. Antagonistic nature of T helper 1/2 developmental programs in opposing peripheral induction of Foxp3+ regulatory T cells. Proc. Natl. Acad. Sci. USA 104: 18169-18174. (Pubitemid 350210839)
32. Chang, J. H., Y. J. Kim, S. H. Han, and C. Y. Kang. 2009. IFN-gamma-STAT1 signal regulates the differentiation of inducible Treg: potential role for ROS-mediated apoptosis. Eur. J. Immunol. 39: 1241-1251.
33. Caretto, D., S. D. Katzman, A. V. Villarino, E. Gallo, and A. K. Abbas. 2010. Cutting edge: the Th1 response inhibits the generation of peripheral regulatory T cells. J. Immunol. 184: 30-34.
34. Bettelli, E., T. Korn, M. Oukka, and V. K. Kuchroo. 2008. Induction and effector functions of T(H)17 cells. Nature 453: 1051-1057. (Pubitemid 351871737)
35. Yang, X. O., R. Nurieva, G. J. Martinez, H. S. Kang, Y. Chung, B. P. Pappu, B. Shah, S. H. Chang, K. S. Schluns, S. S. Watowich, et al. 2008. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 29: 44-56.
36. Olson, T. S., G. Bamias, M. Naganuma, J. Rivera-Nieves, T. L. Burcin, W. Ross, M. A. Morris, T. T. Pizarro, P. B. Ernst, F. Cominelli, and K. Ley. 2004. Expanded B cell population blocks regulatory T cells and exacerbates ileitis in a murine model of Crohn disease. J. Clin. Invest. 114: 389-398. (Pubitemid 39071611)
37. Mariño, E., J. Villanueva, S. Walters, D. Liuwantara, F. Mackay, and S. T. Grey. 2009. CD4(+)CD25(+) T-cells control autoimmunity in the absence of B-cells. Diabetes 58: 1568-1577.
38. Hu, C. Y., D. Rodriguez-Pinto, W. Du, A. Ahuja, O. Henegariu, F. S. Wong, M. J. Shlomchik, and L. Wen. 2007. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J. Clin. Invest. 117: 3857-3867. (Pubitemid 350224095)
39. Yu, S., P. K. Maiti, M. Dyson, R. Jain, and H. Braley-Mullen. 2006. B celldeficient NOD.H-2h4 mice have CD4+CD25+ T regulatory cells that inhibit the development of spontaneous autoimmune thyroiditis. J. Exp. Med. 203: 349-358. (Pubitemid 43290844)
40. Sfikakis, P. P., V. L. Souliotis, K. G. Fragiadaki, H. M. Moutsopoulos, J. N. Boletis, and A. N. Theofilopoulos. 2007. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin. Immunol. 123: 66-73. (Pubitemid 46401511)
41. Stasi, R., N. Cooper, G. Del Poeta, E. Stipa, M. Laura Evangelista, E. Abruzzese, and S. Amadori. 2008. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood 112: 1147-1150.
42. Hanyecz, A., S. E. Berlo, S. Szántó, C. P. Broeren, K. Mikecz, and T. T. Glant. 2004. Achievement of a synergistic adjuvant effect on arthritis induction by activation of innate immunity and forcing the immune response toward the Th1 phenotype. Arthritis Rheum. 50: 1665-1676. (Pubitemid 38608090)
43. Finnegan, A., M. J. Grusby, C. D. Kaplan, S. K. O'Neill, H. Eibel, T. Koreny, M. Czipri, K. Mikecz, and J. Zhang. 2002. IL-4 and IL-12 regulate proteoglycan-induced arthritis through Stat-dependent mechanisms. J. Immunol. 169: 3345-3352. (Pubitemid 35013184)
44. Gavin, M. A., J. P. Rasmussen, J. D. Fontenot, V. Vasta, V. C. Manganiello, J. A. Beavo, and A. Y. Rudensky. 2007. Foxp3-dependent programme of regulatory T-cell differentiation. Nature 445: 771-775. (Pubitemid 46279714)
45. Martin, F., and A. C. Chan. 2006. B cell immunobiology in disease: evolving concepts from the clinic. Annu. Rev. Immunol. 24: 467-496.
46. Josefowicz, S. Z., and A. Rudensky. 2009. Control of regulatory T cell lineage commitment and maintenance. Immunity 30: 616-625.
47. Buckner, J. H. 2010. Mechanisms of impaired regulation by CD4(+)CD25(+) FOXP3(+) regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. 10: 849-859.
48. Rubtsov, Y. P., R. E. Niec, S. Josefowicz, L. Li, J. Darce, D. Mathis, C. Benoist, and A. Y. Rudensky. 2010. Stability of the regulatory T cell lineage in vivo. Science 329: 1667-1671.
49. Wei, G., L. Wei, J. Zhu, C. Zang, J. Hu-Li, Z. Yao, K. Cui, Y. Kanno, T. Y. Roh, W. T. Watford, et al. 2009. Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4+ T cells. Immunity 30: 155-167.
50. Tsuji, M., N. Komatsu, S. Kawamoto, K. Suzuki, O. Kanagawa, T. Honjo, S. Hori, and S. Fagarasan. 2009. Preferential generation of follicular B helper T cells from Foxp3+ T cells in gut Peyer's patches. Science 323: 1488-1492.
51. Matsushita, T., K. Yanaba, J. D. Bouaziz, M. Fujimoto, and T. F. Tedder. 2008. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118: 3420-3430.
52. Weber, M. S., T. Prod'homme, J. C. Patarroyo, N. Molnarfi, T. Karnezis, K. Lehmann-Horn, D. M. Danilenko, J. Eastham-Anderson, A. J. Slavin, C. Linington, et al. 2010. B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann. Neurol. 68: 369-383.
53. Wei, L., A. Laurence, K. M. Elias, and J. J. O'Shea. 2007. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J. Biol. Chem. 282: 34605-34610. (Pubitemid 350232469)
54. Oldenhove, G., N. Bouladoux, E. A. Wohlfert, J. A. Hall, D. Chou, L. Dos Santos, S. O'Brien, R. Blank, E. Lamb, S. Natarajan, et al. 2009. Decrease of Foxp3+ Treg cell number and acquisition of effector cell phenotype during lethal infection. Immunity 31: 772-786.
55. Korn, T., M. Mitsdoerffer, A. L. Croxford, A. Awasthi, V. A. Dardalhon, G. Galileos, P. Vollmar, G. L. Stritesky, M. H. Kaplan, A. Waisman, et al. 2008. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells. Proc. Natl. Acad. Sci. USA 105: 18460-18465.
56. Bardos, T., M. Czipri, C. Vermes, A. Finnegan, K. Mikecz, and J. Zhang. 2003. CD4+CD25+ immunoregulatory T cells may not be involved in controlling autoimmune arthritis. Arthritis Res. Ther. 5: R106-R113.
57. Daniel, C., K.Wennhold, H. J. Kim, and H. von Boehmer. 2010. Enhancement of antigen-specific Treg vaccination in vivo. Proc. Natl. Acad. Sci. USA 107: 16246-16251.
58. Wesley, J. D., B. D. Sather, N. R. Perdue, S. F. Ziegler, and D. J. Campbell. 2010. Cellular requirements for diabetes induction in DO11.10xRIPmOVA mice. J. Immunol. 185: 4760-4768.